Skip to main content

Table 7 Microbiological and clinical information of Cefditoren-resistant isolates

From: Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients

Isolate MIC Cefdi CIP AN AMC AM Cefot CTX CAZ Cefur CXM Cefal CF FOS GM IMP MEC NA NET FT TZP TCC SXT Resistance Phenotype Clinical details available
BA 356 E. coli 1 S S I R S S S S S S S S S S S S S S TEM-1 hyperproduction NA
BA 425 E. coli 1 S S S R S S S S S S S S S S S S S R TEM-1 + SXTR 75ys female AUC, doxycycline in the last 3mos
BC 165 E. coli 1 S S R R S S S R S S S S S S S S S S TEM-1 hyperproduction 25ys female UTI, Hx of UTI in the last 2wks
BC 211 E. coli 1 R S I R S S S R S S S S R S S S S R TEM-1 hyperproduction + SXTR + cross resistance to all fluoroquinolones 81ys female AB with diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2ks and 3 mos, use of CIP in the last 3mos
BTH 486 E. coli 1 S S I R S S S S S S S S S S S S S R TEM-1 hyperproduction + SXTR NA
BM 538 E. coli 1 S S I R S S S R S S S S S S S S S S TEM-1 hyperproduction NA
PER 41ii E. coli 1 S S S R S S S S S S S S S S S S S S TEM-1 45ys male AB, Hx of UTI in the last year
BTH 229 Klebsiella spp 2 S S S R S S S S S S S S S S I S S R SHV-1 natural + FTR + SXTR NA
BP 129 E. coli 2 - S R R S S I R R S S S S S R S S S TEM-1 hyperproduction + FTR + FOSR NA
P 72 Klebsiella spp 2 R S S R S S S S S S S S R S R S S R SHV-1 + FTR + SXTR + cross resistance to all fluoroquinolones 80ys female AB with folley catheter, Hx of UTI in the last 2wks and 3mos, use of cefaclor and TZP in the last 3 months
BK 319 E. coli 4 R S I R S S S S S S S S R S S S S R TEM-1 hyperproduction + SXTR + cross resistance to all fluoroquinolones 18ys female AUC, Hx of UTI in the last 3mos
BA 569 E. coli 16 S S S R R S R R S S S S S S S S S R ESBL CTX-type + SXTR NA
BTH 470 E. coli 32 S S S R R S R R S S S S R S S S S S ESBL CTX-type + Resistance quinolones NalR 40ys female AUC, Hx of UTI in the last year
BM 593 E. coli 32 S S S R R S R R S S S S R S S S S R ESBL CTX-type + SXTR + Resistance quinolones NalR NA
BA 524 Klebsiella spp 64 R S S R R R R R S S S R R S S S S S ESBL + MecilinamR + Cross resistance to all fluoroquinolones NA
BM 463 P. mirabilis 64 S S R R S S S R S S S S S S R S S S AmpC plasmidic + natural FTR 56ys female, fever-frequency-dysuria-pyuria, use of cefaclor in the last 3 mos
BM 465 P. mirabilis 64 S S R R S S S R S S S S S S R S S S AmpC plasmidic + natural FTR 36ys female AUC, history of UTI in the last 3mos and use of CIP
BM 466 P. mirabilis 64 S S R R S S S R S S S S S S R S S S AmpC plasmidic + natural FTR NA
BA 315 E. coli 128 S S I R R S R R S S S S R S S S I I ESBL CTX-type + SXTR + Resistance quinolones NalR 80ys female AB with folley catheter, Hx of UTI in the last 3mos, use of SXT and TZP in the last 3mos, recent hospital admission
GEM 167 E. coli 128 S S I R R S R R S S S S S S S S S R ESBL CTX-type + SXTR NA
GEM 250 E. coli 128 R S S R R S R R S S S S R S S S S R ESBL CTX-type + SXTR + Cross resistance to all fluoroquinolones 68ys female, fever-pyuria, diabetes mellitus and nephrolithiasis, Hx of UTI in the last 2wks and use of CIP, Hx of recent hospital admission
GEM 315 E. coli 128 S R S R R R R R R S S R S S R I S R ESBL + SXTR + FTR + FOSR NA
TZ 250 E. coli 128 R R R R R R R R S R R R R R R R R R MBL (XDR) + Cross resistance to all fluoroquinolones NA
  1. CIP: Ciprofloxacin, AN: Amikacin, AMC: Amoxicillin / clavulanic acid, AM: Ampicillin, CTX: Cefotaxime, CAZ: Ceftazidime, CXM: Cefuroxime, CF: Cephalothin, FOS: Fosfomycin, GM: Gentamicin, IMP: Imipenem, MEC: Mecillinam, NA: Nalidixic acid, NET: Netilmicin, FT: Nitrofurantoin, TZP: Piperacillin / tazobactam, TCC: Ticarcillin / clavulanate, SXT: Trimethoprim / sulfamethoxazole. S: Sensitive, I:Intermediate susceptibility, R: Resistant, NA: not available, AUC: acute uncomplicated cystitis, CUTI: complicated urinary tract infection, AB: asymptomatic bacteriuria, Hx of UTI: history of urinary tract infection.